0001209191-20-009700.txt : 20200214 0001209191-20-009700.hdr.sgml : 20200214 20200214164330 ACCESSION NUMBER: 0001209191-20-009700 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191216 FILED AS OF DATE: 20200214 DATE AS OF CHANGE: 20200214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GUDONIS PAUL R CENTRAL INDEX KEY: 0001015994 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38109 FILM NUMBER: 20621207 MAIL ADDRESS: STREET 1: 9 HICKORY ROAD CITY: MANCHESTER STATE: MA ZIP: 01944 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MYOMO INC CENTRAL INDEX KEY: 0001369290 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-996-9058 MAIL ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-16 0 0001369290 MYOMO INC MYO 0001015994 GUDONIS PAUL R C/O MYOMO, INC. ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 0 1 0 0 Chief Executive Officer Common Stock 2019-12-16 4 A 0 1333 0.00 A 18800 D Common Stock 2020-02-13 4 A 0 1333 0.00 A 20133 D Common Stock 2020-02-13 4 P 0 6000 6.99 A 26133 D Warrants 7.50 2020-02-13 4 P 0 6000 0.01 A 2020-02-13 2025-02-13 Common Stock 6000 6000 D Reporting person was previously granted restricted stock units that may be settled into an aggregate of 6,666 shares of common stock. Upon the achievement of performance criteria, portions of the restricted stock unit grant will commence time-based vesting. The performance criteria for the restricted stock units described in this Report were met and such portion will vest in equal installments on September 25, 2020 and 2021. Shares beneficially owned by this reporting person have been adjusted to reflect a one-for-thirty reverse stock split effected on January 30, 2020. Represents the purchase of common stock and related investor warrant as part of the Company's underwritten public offering, which was completed on February 13, 2020. The investor warrant has an exercise price of $7.50 per share and expires five years from the date of issuance. /s/ Paul Gudonis 2020-02-14